Patent ID: 8227452

Claim:
A method of treating an ocular condition or disease of a human being or an animal, comprising intravitreally administering to a posterior segment of an eye by an invasive means of intraocular injection a medicament or an ophthalmic composition, wherein, said medicament or said ophthalmic composition comprises from 0.8% to about 5% w/w inactive dexamethasone palmitate, said inactive dexamethasone palmitate is hydrolyzed by endogenous enzymes in the posterior segment of the eye to release active dexamethasone for treating said condition or said disease, and said condition or said disease is of the back of the interior of the eye selected from the group consisting of: macular edema, macular degeneration, retinal detachment, ocular tumors, bacterial, fungal and viral infections, multifocal choroiditis, diabetic retinopathy, proliferative vitreoretinopathy (PVR), sympathetic opthalmia, Vogt Koyanagi-Harada (VKH) syndrome, histoplasmosis, uveal diffusion, and vascular occlusion.